Results 231 to 239 of about 44,865 (239)

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New England Journal of Medicine, 2010
Keith T Flaherty, Igor Puzanov, Kevin B Kim   +2 more
exaly  

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Cancer Cell, 2015
Eishu Hirata, Amaya Viros, Michiyuki Matsuda   +2 more
exaly  

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Cancer Cell, 2013
Rizwan Haq, Glenn C Rowe, Abhinav Nellore   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly  

BRAF-/MEK-Inhibition wirksam bei BRAF-V600E-Mutation

Im Fokus Onkologie
openaire   +1 more source

BRAF V600E and Hairy-Cell Leukemia

Cancer Discovery, 2011
openaire   +1 more source

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Cancer Cell
exaly